FATE•benzinga•
Fate Therapeutics Announces New And Updated Clinical Data From First Five Patients Dosed With FT819 For Treatment Of Moderate-To-Severe SLE, At EULAR 2025 Congress
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga